Zaviralec ciklofilina
Zaviralci ciklofilina so potencialna nova skupina zdravil za zdravljenje kronične okužbe z virusom hepatitisa C in zavirajo ciklofiline. Ciklofilini so molekule, pomembne za zvijanje beljakovin ter celični transport in sekrecijo ter pri imunskem odzivu. Virus hepatitisa C izrablja ciklofiline v procesu virusnega podvojevanja in zato zaviralci ciklofilina zavrejo podvojevanje virusa.[1]
Primer zaviralca ciklofilina je učinovina alisporivir.[2] Zavira ciklofilin D, vendar nima imunosupresivnega učinka.[3] Njegovo potencialno uporabnost v zdravljenju kroničnega hepatitisa C še proučujejo.[4][5] Potekajo tudi raziskave o njegovi učinkovitosti pri Duchennovi mišični distrofiji.[2]
Sklici uredi
- ↑ Gaetano J. N., Desai A. P., Reau N. The Era of Direct-Acting Antivirals: The Evolving Role of Interferon and Ribavirin for the Treatment of Chronic Hepatitis C. Clinical Medicine Insights: Therapeutics 2012. 4: 39–56.
- ↑ 2,0 2,1 Reutenauer J; Dorchies OM; Patthey-Vuadens O; Vuagniaux G; Ruegg UT (2008). »Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy«. Br. J. Pharmacol. 155 (4): 574–584. doi:10.1038/bjp.2008.285. PMC 2579666. PMID 18641676.
- ↑ Ptak RG; Gallay PA; Jochmans D; in sod. (2008). »Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent«. Antimicrob. Agents Chemother. 52 (4): 1302–17. doi:10.1128/AAC.01324-07. PMC 2292519. PMID 18212100.
- ↑ Paeshuyse J; Kaul A; De Clercq E; in sod. (2006). »The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro«. Hepatology. 43 (4): 761–770. doi:10.1002/hep.21102. PMID 16557546.
- ↑ Coelmont L; Kaptein S; Paeshuyse J; in sod. (2008). »Debio 025, a cyclophilin binding molecule, is highly efficient in clearing HCV replicon containing cells, alone or when combined with Specifically Targeted Antiviral Therapy for HCV (STAT-C) inhibitors«. Antimicrob. Agents Chemother. 53 (3): 967–76. doi:10.1128/AAC.00939-08. PMC 2650540. PMID 19104013.